Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

Transfusion

Volumn 55, Issue S2, 2015, Pages S36-S46

  Berg, Roger ^a   Shebl, Amgad ^b   Kimber, Mary Clare ^c   Abraham, Maria ^d   Schreiber, George B ^c,e  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b CSL BEHRING GMBH   (Germany)

^c Plasma Protein Therapeutics Association   (United States)

^d University of Iowa   (United States)

^e Plasma Protein Therapeutics Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ABO SYSTEM; HEMAGGLUTININ; IMMUNOGLOBULIN;

BLOOD; BLOOD GROUP ABO SYSTEM; DRUG EFFECTS; FEMALE; HEMOLYSIS; HUMAN; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

ABO BLOOD-GROUP SYSTEM; FEMALE; HEMAGGLUTININS; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84942409923     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/TRF.13198     Document Type: Article

References (24)

1. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983;2:193-5.
2. Copelan EA, Strohm PL, Kennedy MS, et al. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-12.
3. Kim HC, Park CL, Cowan JH, et al. Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. Am J Pediatr Hematol Oncol 1988;10:69-74.
4. FDA Safety Communication: Updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. Date: 11-13-2012. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Nov 14 [cited 2014 Dec 1]. Available from: http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm327934.htm
5. Winiecki S, Baer B, Chege W, et al. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin. Transfusion 2015;55(Suppl 2):S28-S35.
6. Canada Adverse Reaction Newsletter, Volume 19, Issue 4, October 2009, Table 1: Criteria for the standardized case definition of hemolysis associated with the use of intravenous immune globulin (IVIG), as developed by the IVIG Hemolysis Pharmacovigilance Group, p. 2.
7. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598-601.
8. Gordon DJ, Sloan SR, de Jong JL. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol 2009;84:771-2.
9. Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009;4: 1993-7.
10. Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion 2014; 54:681-90.
11. Markvardsen LH, Christiansen I, Harbo T, et al. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Eur J Neurol 2014;21:147-52.
12. Tsukada H, Sunkara R, Chi DD, et al. Intravenous immunoglobulin-induced hemolytic anemia after thoracoscopic thymectomy for myasthenia gravis. Ann Thorac Surg 2014;97:2175-7.
13. Desborough MJ, Miller J, Thorpe SJ, et al. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med 2014;24:219-26.
14. Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci 2012;46:93-6.
15. Public Workshop—Strategies to address hemolytic complications of immune globulin infusions. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Mar 10 [accessed 2014 Dec 1]. Available from: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ WorkshopsMeetingsConferences/ucm378388.htm
16. 16. Blood types. Washington (DC): American Red Cross; 2015 [accessed 2014 Dec 1]. Available from: http://www.red-crossblood.org/learn-about-blood/blood-types
17. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf 2006;29:385-96.
18. Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade. Drug Saf 2012;35: 1171-82.
19. Luban NL, Wong EC, Henrich Lobo R, et al. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Transfusion 2015;55(Suppl 2):S90-S94.
20. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada and the US. JAMA 2003;289:2363-9.
21. Smith RE. The clinical and economical burden of anemia. Am J Manag Care 2010;16:s59-66.
22. Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011;154:644-53.
23. Vermeer NS, Straus SM, Mantel-Teeuwisse AK, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Saf 2013;36:617-25.
24. Jacob D, Marróon B, Ehrlich J, et al. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Health Patient Saf 2013;5:105-12.